Abstract Germline mutations in the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 predispose to Lynch syndrome (also known as hereditary non-polyposis colorectal cancer). Recently, we have shown that the CHEK2 1100delC mutation also is associated with Lynch syndrome/Lynch syndrome-associated families albeit in a polygenic setting. Two of the ten CHEK2 1100delC positive Lynch syndrome families additionally carried a pathogenic MLH1 or MSH6 mutation, suggesting that mutations in mismatch repair genes may be involved in CHEK2 1100delC-associated cancer phenotypes. A phenotype of importance is hereditary breast and colorectal cancer (HBCC), with the CHEK2 1100delC mutation present in almost one-fifth of the families-again in a polygenic setting. In order to evaluate the involvement of MSH6 in polygenic CHEK2 cancer susceptibility, we, here, have analyzed the entire MSH6 coding sequence for genetic alterations in 68 HBCC breast cancer families. Rare MSH6 variants, with population frequencies below 1%, were identified in 11.8% of HBCC breast cancer families, whereas the same variants were identified in only 1.5% of population controls, suggesting that rare MSH6 variants are associated with HBCC breast cancer (P B 0.00001). However, screening of the entire MSH6 coding sequence in 68 non-HBCC breast cancer families showed a similar association (8.8 vs. *1.4% in controls, P B 0.001), suggesting that rare MSH6 variants are not confined to HBCC breast cancer. Together, our data suggest that rare MSH6 variants may predispose to familial breast cancer. However, none of the rare MSH6 variants are obviously pathogenic, suggesting that a more subtle disease mechanism may operate in breast carcinogenesis.
Introduction
In 2002, we and others have identified the truncating CHEK2 1100delC mutation as the first moderate-risk breast cancer susceptibility allele, present in about 5% of Dutch breast cancer families [1, 2] . In addition, we have shown that the CHEK2 1100delC mutation was also present among Lynch syndrome/Lynch syndrome-associated families and was particularly prevalent among breast cancer families with a hereditary breast and colorectal cancer (HBCC) phenotype (4 and 18%, respectively) [3, 4] . However, in each of these instances, CHEK2 1100delC appeared to confer cancer risks in a polygenic setting.
The association of CHEK2 1100delC with colorectal cancer phenotypes suggested known colorectal cancer genes as likely candidates for polygenic CHEK2 cancer susceptibility [4] . Germline mutations in the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 have been identified as the major causes for Lynch syndrome (previously also known as hereditary non-polyposis colorectal cancer, HNPCC; [5] [6] [7] ). Interestingly, in two of the ten CHEK2 1100delC-positive Lynch syndrome-associated families, we had also identified pathogenic mutations in MHL1 or MSH6 [4] . Concomitance of CHEK2 and MSH6 mutations had reportedly also been identified in a Finnish breast cancer family and in the colorectal cancer cell line HCT15 [8] [9] [10] [11] . During repair of DNA damage, activated CHEK2 is known to signal BRCA1, which in turn acts as a scaffold protein for several DNA damage response proteins, including MSH6 [12] [13] [14] . The close functional relation of CHEK2 and MSH6, together with the observed concomitance of mutations in the two genes suggested that MSH6 mutations may be involved in CHEK2 polygenic cancer susceptibility. This hypothesis was particular appealing for the HBCC phenotype as CHEK2 1100delC is prevalent among these families, whereas MSH6 mutations are identified among Lynch syndrome families that also include breast cancer [3, [15] [16] [17] . Here, we therefore have screened the MSH6 gene for genetic alterations in 68 HBCC and 68 non-HBCC breast cancer families.
Patients and methods

Breast cancer families and population controls
One hundred thirty-six breast cancer families were selected from 578 breast cancer families registered at the Rotterdam Family Cancer Clinic at Erasmus MC. Breast cancer families were classified as hereditary breast and colorectal cancer (HBCC) families (n = 68) or non-HBCC families (n = 68). All families included at least two-first or seconddegree relatives (DGRs) with breast cancer of whom at least one was diagnosed before the age of 60 years. HBCC families additionally included at least one patient with breast and colorectal cancer or at least one patient with colorectal cancer diagnosed before the age of 50 years who is within second DGR of a breast cancer patient or at least two colorectal cancer patients of whom at least one is within second DGR of a breast cancer patient [3] .
All breast cancer families were screened for germline mutations in the BRCA1 and BRCA2 genes and the CHEK2 1100delC mutation, identifying 26 BRCA1 mutant families, 6 BRCA2 mutant families, and 18 families with the CHEK2 1100delC mutation. Two families were double mutant for BRCA1 and the CHEK2 1100delC mutation. As part of our matching procedure, mutant BRCA1, BRCA2, and CHEK2 1100delC families were equally divided over HBCC and non-HBCC families. Pathogenic germline mutations in the MLH1 and MSH2 genes were not identified in any of the 68 HBCC families. MLH1 and MSH2 mutation status had not been determined for the 68 non-HBCC families.
All breast cancer families originated from the southwestern Netherlands and have consented to search for cancer susceptibility genes. The 166 control individuals were geographically matched to the familial breast cancer cases and included spouses of heterozygous carriers of cystic fibrosis gene mutations, ascertained through the department of Clinical Genetics at Erasmus MC. The medical ethical committee of Erasmus MC approved this study.
MSH6 mutation analysis
The mismatch repair gene MSH6 (NM_000179.2) was screened for mutations in blood-derived DNA of the youngest diagnosed breast cancer case in the family (index case). The complete coding sequence of the MSH6 gene, including intron/exon boundaries up to 25 bases in the intron, was amplified by standard PCR. Amplified fragments were subsequently analyzed for genetic alterations by denaturing gradient gel electrophoresis (DGGE) or by direct sequencing as described [17] [18] [19] . Unique sequence alterations were confirmed at least once by sequence analysis of an independently generated PCR product. Primer sequences and reaction conditions are available upon request.
Statistical analysis
The difference between the mutation frequency in breast cancer patients versus controls was analyzed using Fisher's Exact Test. P values of 0.05 or smaller were considered significant. All statistical analyses were performed with STATA statistical package, release 10 (STATA Corp, College Station, TX).
Results and discussion
Rare MSH6 variants associate with HBCC breast cancer We analyzed the entire MSH6 coding sequence in 68 breast cancer families with hereditary breast and colorectal cancer (HBCC). Sequence analysis identified 25 different sequence alterations among 68 HBCC families, including 10 intronic and 15 exonic variants (Table 1) . In order to evaluate the significance of the identified MSH6 variants for HBCC, all variants were subsequently genotyped in 166 geographically matched controls. Rare variants, with population frequencies below 1%, represented 56% (14/25) of the MSH6 variants and each of these were identified only once or twice among the HBCC cohort. Four of the 14 rare MSH6 variants identified among HBCC families were also identified in the control cohort. Thus, although none of the In order to evaluate if rare MSH6 variants associate with HBCC breast cancer or rather with familial breast cancer in general, we also screened the entire MSH6 coding sequence in 68 matched non-HBCC families (Table 1) . Non-HBCC families were matched to the HBCC families with respect to their cancer pattern, i.e., the number of cancer patients per family, the number of cancer patients overall and the number of patients with single, double, triple, or more cancers (Table 2 ). In order to avoid selection for HBCC, the non-HBCC families have been counter selected for the presence of colorectal cancer. Six additional rare MSH6 variants were identified among the non-HBCC families of which only one was also identified among the controls ( Table 1 ). The combined frequency of rare MSH6 variants was also significantly higher among non-HBCC families compared to controls (12/136 (8.8%) vs. 4/254-332 (*1.4%), P \ 0.001; Table 1 ). Hence, the prevalence of rare MSH6 variants among non-HBCC families is equally high as among HBCC families, indicating that rare MSH6 variants are not only associated with HBCC breast cancer but also more likely with breast cancer in general. Combining the data on HBCC and non-HBCC families revealed a prevalence of rare MSH6 variants of 10.3% among all breast cancer families, whereas the same variants were identified in approximately 2.1% of controls (P \ 0.0001; Table 1 ), strongly suggesting that rare MSH6 variants may predispose for familial breast cancer.
Do rare MSH6 variants predispose for familial breast cancer?
Two aspects may question whether rare MSH6 variants indeed predispose for familial breast cancer. First, we have not screened the entire MSH6 coding sequence in the control cohort. Our strategy had been to genotype in the controls only those MSH6 variants that had been identified among the familial breast cancer cohorts. Apart from the genotyped variant sequence, our primer design allowed analysis of the sequence surrounding the genotyped variant often including entire exon sequences and intron sequences up to 25 base pairs. In this way, we were able to analyze 75% of the MSH6 coding sequence in all controls. In addition to the five rare MSH6 variants that already had been identified in the breast cancer families, two variants (c.59C [ T, p.A20 V and c.4002-10delCT) were once identified exclusively among the controls. Based on this low prevalence of rare MSH6 variants that are exclusively present among the controls (2/254 (0.8%); Table 1 ), it may be anticipated that screening of the remaining quarter of the MSH6 coding sequence in the controls is unlikely to identify many more rare MSH6 variants. Another aspect is that the underlying disease mechanism of how rare MSH6 variants may predispose to breast cancer. We found that the prevalence of rare MSH6 variants was consistently higher among the breast cancer families than the controls, whether they were intronic or exonic and whether they were synonymous or non-synonymous. However, none of the identified rare MSH6 variants are known pathogenic mutations. Evaluation of each of the rare MSH6 variants with the splice prediction programs Berkeley Drosophila Genome Project (www.fruitfly.org/seq_tools/splice. html) and NetGene2 (www.cbs.dtu.dk./services/NetGene2/) did not predict structural effects. It thus remains unclear how these rare MSH6 variants exert their putative oncogenic effect, particularly for the intronic variants and the nonsynonymous exonic variants. However, are obvious pathogenic effects to be expected in a polygenic setting? Importantly, the statistical evidence from our analysis that rare MSH6 variants associate with familial breast cancer is compelling (P \ 0.001), strongly suggesting cancer predisposition by rare MSH6 variants. Obviously, our analysis requires replication in independent familial breast cancer cohorts, and it also seems warranted to screen familial colorectal cancer cohorts, with particular focus to rare variants that are not obviously pathogenic. In this respect, our current findings are consistent with a report by Nevanlinna et al. in which 15 different MSH6 variants were identified among 38 breast cancer families with colorectal cancer and/or endometrial cancer [20] . Three of the MSH6 variants classified as rare variants, including two synonymous exonic variants and one intronic variant. The prevalence of rare MSH6 variants in their familial breast cancer cohort is similar to the prevalence we report here (3/38 = 7.9 vs. 10.3% in our cohort) and supports our conclusion that rare MSH6 variants are associated with familial breast cancer. Their and our observations both seem to point toward a currently unknown disease mechanism in breast carcinogenesis such as modulation of transcript expression levels or mediation of non-coding RNAs located in the genomic regions associated with these variants. Therefore, one may wonder whether this mechanism is similar to the as-yet unresolved disease mechanism underlying the more prevalent low-risk breast cancer alleles that recently have received much attention [21] [22] [23] [24] [25] [26] .
